📊 NUVB Key Takeaways
Is Nuvation Bio Inc. (NUVB) a Good Investment?
Nuvation Bio maintains a fortress balance sheet with exceptional liquidity ($125.4M cash, 7.44x current ratio) and minimal leverage, but operational fundamentals are concerning with flat revenue growth and a critical interest coverage ratio of 0.4x. The company's reliance on non-operating income to achieve profitability, combined with anemic returns (ROE 1.7%, ROA 0.9%), indicates structural operational challenges that outweigh balance sheet strength.
Balance sheet strength (current 6.95x, quick 6.81x) and low leverage provide meaningful runway while losses narrowed YoY. However, revenue is flat with low gross margin and operating/FCF remain deeply negative, keeping profitability distant and elevating financing risk if burn persists.
Why Buy Nuvation Bio Inc. Stock? NUVB Key Strengths
- Fortress balance sheet with $125.4M in cash and very low leverage (Debt/Equity of 0.15x)
- Exceptional liquidity with 7.44x current ratio and 7.24x quick ratio providing substantial financial flexibility
- Positive profitability with $5.4M net income and $5.1M free cash flow demonstrating operational cash generation
- Diluted EPS grew 71.6% year-over-year showing per-share metric improvement
- Strong liquidity (current 6.95x, quick 6.81x)
- Low leverage (0.15x D/E) with positive equity base
- Material YoY improvement in EPS and net loss
NUVB Stock Risks: Nuvation Bio Inc. Investment Risks
- Interest coverage ratio of 0.4x is critically low, indicating operating income covers only 40% of interest obligations and is unsustainable long-term
- Flat revenue growth at 0% YoY with no top-line momentum in a competitive pharmaceutical sector
- Severely weak returns with ROE of 1.7% and ROA of 0.9% demonstrating poor capital efficiency and asset utilization
- Net income exceeds operating income, indicating reliance on non-operating gains rather than sustainable operational profitability
- Sustained heavy cash burn and negative FCF (-$173.43M; -275.7% margin)
- Deeply negative margins and returns (operating, net, ROE/ROA)
- Financing/dilution risk given negative interest coverage and ongoing losses
Key Metrics to Watch
- Revenue growth acceleration and new product pipeline progress to reverse flat sales trajectory
- Interest coverage ratio improvement toward 2.5x+ sustainable levels through improved operating income
- Return on equity and ROA expansion to demonstrate meaningful progress on capital efficiency
- Operating cash flow consistency and free cash flow sustainability to validate cash generation capability
- Operating cash flow (TTM)
- Revenue growth (YoY)
Nuvation Bio Inc. (NUVB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.44x current ratio provides a solid financial cushion.
NUVB Profit Margin, ROE & Profitability Analysis
NUVB vs Healthcare Sector: How Nuvation Bio Inc. Compares
How Nuvation Bio Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nuvation Bio Inc. Stock Overvalued? NUVB Valuation Analysis 2026
Based on fundamental analysis, Nuvation Bio Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nuvation Bio Inc. Balance Sheet: NUVB Debt, Cash & Liquidity
NUVB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nuvation Bio Inc.'s revenue has grown significantly by 699% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.11 indicates the company is currently unprofitable.
NUVB Revenue Growth, EPS Growth & YoY Performance
NUVB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.1M | $5.4M | $0.01 |
| Q3 2025 | $727.0K | -$14.8M | $-0.15 |
| Q2 2025 | $1.4M | -$14.8M | $-0.17 |
| Q1 2025 | N/A | -$14.8M | $-0.07 |
| Q3 2024 | N/A | -$14.8M | $-0.09 |
| Q2 2024 | N/A | -$14.8M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nuvation Bio Inc. Dividends, Buybacks & Capital Allocation
NUVB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nuvation Bio Inc. (CIK: 0001811063)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUVB
What is the AI rating for NUVB?
Nuvation Bio Inc. (NUVB) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUVB's key strengths?
Claude: Fortress balance sheet with $125.4M in cash and very low leverage (Debt/Equity of 0.15x). Exceptional liquidity with 7.44x current ratio and 7.24x quick ratio providing substantial financial flexibility. ChatGPT: Strong liquidity (current 6.95x, quick 6.81x). Low leverage (0.15x D/E) with positive equity base.
What are the risks of investing in NUVB?
Claude: Interest coverage ratio of 0.4x is critically low, indicating operating income covers only 40% of interest obligations and is unsustainable long-term. Flat revenue growth at 0% YoY with no top-line momentum in a competitive pharmaceutical sector. ChatGPT: Sustained heavy cash burn and negative FCF (-$173.43M; -275.7% margin). Deeply negative margins and returns (operating, net, ROE/ROA).
What is NUVB's revenue and growth?
Nuvation Bio Inc. reported revenue of $83.2M.
Does NUVB pay dividends?
Nuvation Bio Inc. does not currently pay dividends.
Where can I find NUVB SEC filings?
Official SEC filings for Nuvation Bio Inc. (CIK: 0001811063) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUVB's EPS?
Nuvation Bio Inc. has a diluted EPS of $0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUVB a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Nuvation Bio Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUVB stock overvalued or undervalued?
Valuation metrics for NUVB: ROE of 1.7% (sector avg: 15%), net margin of 6.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NUVB stock in 2026?
Our dual AI analysis gives Nuvation Bio Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUVB's free cash flow?
Nuvation Bio Inc.'s operating cash flow is $5.1M, with capital expenditures of N/A. FCF margin is 6.1%.
How does NUVB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.5% (avg: 12%), ROE 1.7% (avg: 15%), current ratio 7.44 (avg: 2).